Anúncio
Anúncio
GRCE
Grace Therapeutics, Inc. Common Stock
3.71
USDPatrocinado
-0.09
-2.50%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
3.83
+0.12
+3.24%
Relatórios de Lucros GRCE
Rácio de surpresa positiva
GRCE separação 14 de 22 últimas estimativas.
64%
Próximo Relatório
Data do Próximo Relatório
13 de fev. de 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.28
Mudanças implicadas de Q2 26 (Revenue/ EPS)
--
/+366.67%
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/+7.69%
Grace Therapeutics, Inc. Common Stock earnings per share and revenue
On 13 de nov. de 2025, GRCE reported earnings of -0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.18 USD, resulting in a 68.20% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analistas forecast an EPS of -0.28 USD, with revenue projected to reach -- USD, implying an aumentar of 366.67% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Grace Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Grace Therapeutics, Inc. Common Stock reported EPS of -$0.06, beating estimates by 68.2%, and revenue of $0.00, 0% as expectations.
How did the market react to Grace Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 2.31%, changed from $3.03 before the earnings release to $3.10 the day after.
When is Grace Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 13 de fev. de 2026.
What are the forecasts for Grace Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analistas, Grace Therapeutics, Inc. Common Stock is expected to report EPS of -$0.28 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio